| Literature DB >> 27299710 |
Chang Ching Liu1, Dong Liang Ma2,3, Ting-Dong Yan1, XiuBo Fan1,4, Zhiyong Poon5, Lai-Fong Poon1, Su-Ann Goh1, Steve G Rozen1, William Ying Khee Hwang1,4, Vinay Tergaonkar6,7,8, Patrick Tan1, Sujoy Ghosh9, David M Virshup1, Eyleen L K Goh2,3,10,11, Shang Li12,13.
Abstract
In most human somatic cells, the lack of telomerase activity results in progressive telomere shortening during each cell division. Eventually, DNA damage responses triggered by critically short telomeres induce an irreversible cell cycle arrest termed replicative senescence. However, the cellular responses of human pluripotent stem cells to telomere uncapping remain unknown. We generated telomerase knockout human embryonic stem (ES) cells through gene targeting. Telomerase inactivation in ES cells results in progressive telomere shortening. Telomere DNA damage in ES cells and neural progenitor cells induces rapid apoptosis when telomeres are uncapped, in contrast to fibroblast cells that enter a state of replicative senescence. Significantly, telomerase inactivation limits the proliferation capacity of human ES cells without affecting their pluripotency. By targeting telomerase activity, we can functionally separate the two unique properties of human pluripotent stem cells, namely unlimited self-renewal and pluripotency. We show that the potential of ES cells to form teratomas in vivo is dictated by their telomere length. By controlling telomere length of ES cells through telomerase inactivation, we can inhibit teratoma formation and potentially improve the safety of cell therapies involving terminally differentiated cells as well as specific progenitor cells that do not require sustained cellular proliferation in vivo, and thus sustained telomerase activity. Stem Cells 2016;34:2471-2484.Entities:
Keywords: Cellular therapy; Malignancy; Pluripotent stem cells; Stem cell transplantation; Telomerase; Telomere
Mesh:
Substances:
Year: 2016 PMID: 27299710 DOI: 10.1002/stem.2431
Source DB: PubMed Journal: Stem Cells ISSN: 1066-5099 Impact factor: 6.277